pharmaphorum

SEPTEMBER 22, 2021

Analysts said that the warning, which follows an FDA review of the safety of the JAK inhibitor class, could put a brake on sales of the new drug. European regulators have also already approved Olumiant and Rinvoq for the inflammatory skin disorder.

Sales 52

Sales Regulation FDA Approval Marketing 52

The Pharma Data

AUGUST 3, 2021

Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). Product Sales Performance. Key results include: Total revenues increased 5% to $6.5

Sales 52

Sales Production Antibody Development 52

pharmaphorum

OCTOBER 28, 2020

The US regulator has started a priority review of abrocitinib for mediate to severe atopic dermatitis in patients aged over 12, setting up a decision next April, while the EMA has also started a standard review that could lead to approval in the EU in the second half of 2021.

Drugs 52

Drugs Sales Marketing FDA Approval 52

Delveinsight

AUGUST 25, 2021

They are governed by a number of rules and regulations that govern drug patenting, testing, safety, efficacy, and marketing. . The combined sales of the Immunology (15%) and Oncology (38%) sectors were more than 50% of the total revenue in 2020. They both made a sale of USD 3.8 The global healthcare spending in 2020 was USD 8.3

Vaccination 98

Vaccination Vaccine Sales Drugs 98

pharmaphorum

MAY 25, 2022

Vtama (tapinarof) – originally developed by GlaxoSmithKline – is a first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) and has been approved by the US regulator with a broad label spanning mild, moderate, and severe psoriasis and an unlimited duration of use.

Drugs 52

Drugs FDA Approval Licensing Licensing 52

The Pharma Data

AUGUST 1, 2021

Under the agreement AstraZeneca will pay BMS a low to mid-teens royalty for sales dependent on geography. 4 Type I IFNs such as IFN-alpha, IFN-beta and IFN-kappa are cytokines involved in regulating the inflammatory pathways implicated in SLE. 17,18 At least five million people worldwide have a form of lupus.

Trials 52

Trials Clinical Development Antibody Dermatology 52

The Pharma Data

DECEMBER 17, 2020

Martin Carter Professor in Clinical Investigation and Head of the Laboratory of Investigative Dermatology at The Rockefeller University and Weinblatt is the co-director of Clinical Rheumatology at the Brigham and Women’s Hospital. Immune Regulation – U.K.-based based Immune Regulation Ltd. He spent 27 years at Merck & Co.

Development 52

Development Gene Therapy Engineer Life Science 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 52

Production Dermatology Development Containment 52

pharmaphorum

JUNE 8, 2021

In return, it is handing over a capped single-digit percentage royalty interest in net sales of the drug to the investors, which include Marathon Asset Management, NovaQuest Capital Management and a third unnamed party. billion takeover of Constellation Pharma. It is also due to start a phase 3 trial in atopic dermatitis later this year.

Sales 52

Sales Dermatology Licensing Licensing 52

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 40

Production Dermatology Development Containment 40

pharmaphorum

JANUARY 5, 2021

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed. Price and value battleground.

Sales 105

Sales Marketing Production Vaccination 105

The Pharma Data

APRIL 26, 2021

Q1 net sales declined -2% (cc¹, +1% USD), due to prior year COVID-19 related forward purchasing (approximately USD 0.4 Kesimpta sales reached USD 50 million. Adakveo sales reached USD 37 million. Sandoz sales declined -13% (cc, -9% USD), with Retail -18% (cc) and Biopharmaceuticals growing +7% (cc). Operating income.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

JANUARY 13, 2021

(IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. Source link.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

JANUARY 6, 2021

Nasdaq: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the pricing of its previously announced underwritten public offering of 4,237,288 shares of its common stock at a price to the public of $29.50 7, 2021 05:00 UTC. LA JOLLA, Calif.–(

Dermatology 40

Dermatology Genome Genomics Production 40